Eupraxia Pharmaceuticals is trading 6.54% up at $7.17 based on the provided live price; the catalyst remains unconfirmed.
- No new company-specific announcement dated August 24, 2026, was identified.
- The latest notable disclosure was August 13 RESOLVE trial symptom-response data, including sustained improvements and no reported serious adverse events; available coverage does not explicitly connect it to the current move.
- The broader market is mixed to lower.